Guangdong Province Key Laboratory of Arrhythmia and Electrophysiology, Department of Cardiology, Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, PR China.
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetic and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, PR China.
Life Sci. 2019 Jul 1;228:72-84. doi: 10.1016/j.lfs.2019.04.050. Epub 2019 Apr 26.
Calcific aortic valve disease (CAVD) emerges as a challenging clinical issue, which is associated with high cardiovascular mortality. It has been demonstrated that osteoblastic transformation of AVICs is a key mechanism of CAVD and C-C motif chemokine receptors (CCRs) may favor this process. Thus, we aimed to investigate whether CCRs were involved in osteoblastic transformation of AVICs during the development CAVD.
We first analyzed microarray data (GSE51472 and GSE12644) to identify differentially expressed genes between CAVD aortic valve tissue and normal samples, followed by verification of immunohistochemistry, qPCR and western blotting. Primary aortic valvular interstitial cells (AVICs) were incubated with specific inhibitors and/or siRNA of CCR2 and CCL2 under pro-calcifying medium. The levels of CCL2 in the medium were measured by ELISA. In addition, we used recombinant CCL2 to activate CCR2 in calcifying AVICs. Alizarin red S staining and calcium deposition were used to evaluate the degree of calcification. Western blotting was used to determine osteoblastic transformation of AVIC and total Akt and phosphorylated Akt expression.
CCR2 levels were remarkably up-regulated in calcified aortic valve and calcifying AVICs. Silencing CCR2 inhibited the osteoblastic transformation and calcification of AVICs. In addition, recombinant CCL2 activated CCR2 and accelerated AVICs calcification through PI3K/Akt pathway.
We characterize abnormal activation of CCL2/CCR2 axis as a promoter of AVICs osteoblastic transformation and calcification. Our findings implicate the CCL2/CCR2-PI3K/Akt pathway as a potential target for treatment of CAVD.
钙化性主动脉瓣疾病(CAVD)是一个具有挑战性的临床问题,与心血管死亡率高有关。已经证明,AVIC 的成骨细胞转化是 CAVD 的一个关键机制,而 C-C 基序趋化因子受体(CCRs)可能有利于这一过程。因此,我们旨在研究 CCRs 是否参与 CAVD 发展过程中 AVIC 的成骨细胞转化。
我们首先分析了微阵列数据(GSE51472 和 GSE12644),以鉴定 CAVD 主动脉瓣组织与正常样本之间差异表达的基因,随后通过免疫组织化学、qPCR 和 Western blot 进行验证。在促钙化培养基中,将原代主动脉瓣膜间质细胞(AVICs)与 CCR2 和 CCL2 的特异性抑制剂和/或 siRNA 孵育。ELISA 法测定培养基中 CCL2 的水平。此外,我们使用重组 CCL2 激活钙化 AVIC 中的 CCR2。茜素红 S 染色和钙沉积用于评估钙化程度。Western blot 用于确定 AVIC 的成骨细胞转化和总 Akt 及磷酸化 Akt 的表达。
CCR2 水平在钙化主动脉瓣和钙化 AVIC 中显著上调。沉默 CCR2 抑制了 AVIC 的成骨细胞转化和钙化。此外,重组 CCL2 通过 PI3K/Akt 通路激活 CCR2 并加速 AVICs 钙化。
我们将 CCL2/CCR2 轴的异常激活特征化为 AVIC 成骨细胞转化和钙化的促进剂。我们的研究结果表明,CCL2/CCR2-PI3K/Akt 通路可能是治疗 CAVD 的潜在靶点。